Here's Why GlycoMimetics Could Become a Takeover Target

Here's Why GlycoMimetics Could Become a Takeover Target

Updated results from a trial evaluating GMI-1271 in relapsed or refractory acute myeloid leukemia (AML) sent GlycoMimetics (NASDAQ: GLYC) shares soaring earlier this week, but more good news next year could send shares even higher next year.

The company plans to begin a phase 3 study of GMI-1271 by the middle of 2018, and in the second half of 2018, data is expected from a phase 3 study evaluating GlycoMimetics and Pfizer's (NYSE: PFE) sickle-cell disease drug, rivipansel.

The potential to improve AML treatment and improve the lives of sickle-cell disease patients could make this company an intriguing takeover target, so let's learn more about GlycoMimetics' story.

Continue reading

Source: Fool.com